Anderson CM et al. ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC). ASCO 2022;Abstract 6005.
Capdevila J et al. Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes. ASCO 2022;Abstract 6081.
Clump DA et al. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). ASCO 2022;Abstract 6007.
Drilon AE et al. Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer. ASCO 2022;Abstract 3100.
Flach S et al. Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS): A personalized cell-free tumor DNA analysis for patients with HNSCC. ASCO 2022;Abstract 6017.
Hernando J et al. Cabozantinib (C) versus placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on prior VEGFR-targeted therapy. ASCO 2022;Abstract 6083.
Kolarski MM et al. Effectiveness of adjuvant chemoradiotherapy for oral cavity squamous cell carcinoma with minor and major extranodal extension: A multi-institutional consortium study. ASCO 2022;Abstract 6010.
Krzakowski MJ et al. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. ASCO 2022;Abstract 3099.
Kummar S et al. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. ASCO 2022;Abstract 6563.
Mansfield AS et al. Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial. ASCO 2022;Abstract 6080.
Patil VM et al. Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer. ASCO 2022;Abstract LBA6016.
Saba NF et al. A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). ASCO 2022;Abstract 6008.
Sharma A et al. An open label, noninferiority phase III RCT of weekly vs three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial). ASCO 2022;Abstract 6004.
Tarasova V et al. Characterization of genomic landscape using comprehensive circulating cell-free tumor DNA next generation sequencing in advanced thyroid carcinoma. ASCO 2022;Abstract 3045.
Yom SS et al. Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002. ASCO 2022;Abstract 6006.